Leiomyosarcoma occurring as a primary cardiac tumor has been known as an extremely rare condition. Previous studies of leiomyosarcoma with rhabdomyoblastic differentiation have conducted to those arisen from another site, and they indicated a poorer prognosis of this tumor.
Case presentation
A 69-year-old woman was referred to our hospital for an operation concerning umbilical hernia. Subsequent imaging examinations before an operation indicated the presence of primary cardiac malignant tumor due to its atypical shape. And then, it was surgically removed. Histopathologically, tumor cells consisted of two different types: spindle and polyhedral cells. Immunohistochemically, it is interesting to note that 2.1% of spindle cells and 23.1% of polyhedral cells showed positive reactivity for myogenin. Furthermore, we performed double-immunostaining for alpha-smooth muscle actin (SMA) and myogenin. The rates of alpha-SMA and myogenin double negative, alpha-SMA single positive, myogenin single positive, and alpha-SMA and myogenin double positive in spindle cells were estimated as 69.1%, 28.8%, 1.1% and 1.0%, respectively. In contrast, the rates in polyhedral cells were estimated as 76.9%, 0.0%, 23.1%, and 0.0%, respectively.
Conclusion
Our immunohistochemical evaluation suggested that rhabdomyoblastic differentiation in leiomyosarcoma might be generated not only by de novo generation from mesenchymal cells. To the best of our knowledge, this is the first case of primary cardiac leiomyosarcoma with partial rhabdomyoblastic differentiation.
The online version of this article (doi:10.1186/1471-2407-11-76) contains supplementary material, which is available to authorized users.
Competing interests
Dr. Shibuya reports receiving research grants from Pfizer Japan Inc., Janssen Pharmaceutical K.K., and Dainippon Sumitomo Pharma Co. All authors declare that they have no competing interests.
Authors' contributions
YO conceptualized the case report, integrated the data, and wrote the manuscript as a major contributor; KS carried out the histopathological evaluation and revised the manuscript; AN contributed to management of the patient and revised clinical description; KT contributed to management of the patient and gave final approval to the manuscript as a corresponding author; NK, TN, AM, and MW carried out the histopathologic evaluation and revised histopathological description; MS, NH, KK, and IT carried out the histopathologic evaluation, JY contributed to management of the patient as a chief doctor of Division of Cardiovascular Medicine. All authors have read and approved the final manuscript.
Background
Primary cardiac tumors represent a rare neoplastic condition with an incidence that ranges from 0.0017 to 0.019% [1], of which 25% are malignant. Among such tumors, angiosarcoma is the commonest malignant tumor followed by rhabdomyosarcoma, malignant mesothelioma, and fibrosarcoma, each with an incidence that is greater than 10% [2]. However, the incidence of cardiac leiomyosarcoma is less than 1% [2]. Previous studies of leiomyosarcoma with rhabdomyoblastic differentiation have conducted to those arisen from another site [3‐11], and they announced a poorer prognosis of this tumor. Especially, Oshiro et al. have reported that leiomyosarcoma with rhabdomyoblastic differentiation shows poorer prognosis than typical leiomyosarcoma [6]. In the present paper, we describe an extremely rare primary cardiac malignant tumor. To the best of our knowledge, this is the first case of primary cardiac leiomyosarcoma with partial rhabdomyoblastic differentiation.
Case presentation
A 69-year-old woman was referred to our hospital for an operation concerning umbilical hernia who had been diagnosed with hypertension and polycystic kidney disease one year prior to her surgery. Subsequent transthoracic cardiac ultrasonography in our hospital showed a club-shaped tumor of 34 mm in diameter inside the left atrial cavity in a four-cavities tomogram. Transesophageal cardiac ultrasonography showed a broad-based, gigantic, and multilocular tumor occupying almost the entire left atrium (Figure 1). Chest computed tomography (CT) showed no abnormality in the lungs or hilar lymph nodes. Abdominal CT showed multilocular cysts in bilateral kidneys. Cardiac magnetic resonance imaging showed a broad-based protuberant tumor which had a T1 iso-signal intensity and high T2 signal intensity in the posterior wall of the left atrium. Positron emission tomography analysis showed abnormal 18F- fluorodeoxy glucose uptake which was detected only in the heart, with the exception of the umbilical hernia lesion. These results indicated the presence of primary cardiac malignant tumor due to its atypical shape. Finally, surgical removal with the patient's permission was performed. Almost all of the tumor could be removed and subsequent chemotherapy was considered. However, the patient's renal dysfunction ruined adjuvant chemotherapy and she died of her disease nine months after the surgical removal due to multiple lung metastases.
×
Anzeige
Pathologic findings
Macroscopically, the submitted specimen comprised several cakes of the tumor with a gray-white color on the surface (Figure 2). It was fixed with 10% buffered formalin, embedded in paraffin wax after dehydration, and cut into four μm-thick sections. These were then prepared and stained with hematoxylin and eosin (HE) double stain for light microscopic observation.
×
Histopathologically, tumor cells that had proliferated in the myxoedematous matrix (Figure 3A) consisted of two different types: a large portion comprised spindle cells, and polyhedral cells were also identified as a minor component. Spindle cells had an elongated, blunt-ended and hyperchromatic nucleus plus spindle, were fibrillated and possessed an eosinophilic cytoplasm (Figure 3D and 4A). In contrast, polyhedral cells had a hyperchromatic and eccentric nucleus with a polyhedral, large, and eosinophilic cytoplasm (Figure 5A). Spindle cells showed twelve mitoses per ten high-power fields. Accordingly, the histological grade of the tumor corresponded to grade-2 (tumor differentiation: score-2; mitotic counts: score-2; tumor necrosis: score-1) following to the French National Federation of Cancer Centers (FNCLCC) grading system (Figure 3C and 3D) [12].
×
×
×
Although a few polyhedral cells were confirmed, morphological findings on HE double stain indicated a myxoid type of leiomyosarcoma.
Immunohistochemical findings
Several kinds of monoclonal antibody were used to evaluate tumor cells immunohistochemically and included anti-Vimentin, CD31, CD34, cytokeratin (CK AE1/AE3, 34 β-E 12, 5/6, and CAM 5.2), desmin, α-smooth muscle actin (α-SMA), myoglobin, myogenin, and Ki-67 (MIB-1) antibodies. All tumor cells showed strong positive reactivity for vimentin and negative reactivity for CD31, CD34, and myoglobin (Figure 4D and 5D). Spindle cells showed focal positive reactivity for desmin, α-SMA, and cytokeratin CAM 5.2 (Figure 4B, C, and 4F). In contrast, polyhedral cells showed positive reactivity for desmin, but negative reactivity for α-SMA and cytokeratin CAM 5.2 (Figure 5B, C, and 5F). Ki-67 (MIB-1) labeling index in the spindle and polyhedral cells were estimated as 27.1% and 33.3%, respectively. It is interesting to note that 2.1% of spindle cells and 23.1% of polyhedral cells showed positive reactivity for myogenin (Figure 4E and 5E). Furthermore, to determine whether tumor cells are present as double positive for both α-SMA and myogenin, and to ascertain the morphological characteristics of these tumor cells, we performed double-immunostaining for α-SMA and myogenin. The rates of α-SMA and myogenin double negative, α-SMA single positive, myogenin single positive, and α-SMA and myogenin double positive in spindle cells were estimated as 69.1%, 28.8%, 1.1%, and 1.0%, respectively (Figure 6A, B, C, and 6D). In contrast, the rates in polyhedral cells were estimated as 76.9%, 0.0%, 23.1%, and 0.0%, respectively. These results are summarized in Table 1. According to the morphological and immunohistochemical findings, we diagnosed this primary cardiac tumor as a leiomyosarcoma with partial rhabdomyoblastic differentiation.
×
Anzeige
Table 1
Summary of phenotypical expression by immunohistochemical examination
Spindle cell
Polyhedral cell
α-SMA and myogenin double negative
α-SMA (-) and myogenin (-)
69.1%
76.9%
α-SMA single positive
α-SMA (+) and myogenin (-)
28.8%
0.0%
myogenin single positive
α-SMA (-) and myogenin (+)
1.1%
23.1%
α-SMA and myogenin double positive
α-SMA (+) and myogenin (+)
1.0%
0.0%
SMA: smooth muscle actin
The rates of α-SMA and myogenin double negative, α-SMA single positive, myogenin single positive, and α-SMA and myogenin double positive in spindle cells were estimated as 69.1%, 28.8%, 1.1% and 1.0%, respectively.
Discussion
Leiomyosarcoma occurring as a primary cardiac tumor has been known as an extremely rare condition of which the rate represents less than 1% of all primary cardiac malignant tumors [2]. Furthermore, to the best of our knowledge there has been no report of a case of primary cardiac leiomyosarcoma with partial rhabdomyoblastic differentiation. In general, leiomyosarcoma is currently subdivided histologically into four types: classical, epithelioid, pleomorphic, and myxoid [13]. The morphological findings of the present case indicated a myxoid type of leiomyosarcoma, but immunohistochemistry revealed that a few tumor cells showed positive reactivity for myogenin. This has been known as a myogenic transcriptional regulatory protein which is expressed in the early phase of skeletal muscle differentiation (rhabdomyogenic differentiation), and it induces differentiation of myoblasts into the multinucleated myotube [14]. This myogenic regulatory protein has been largely accepted as a sensitive and specific immunohistochemical marker for rhabdomyosarcoma or other tumors with rhabdomyoblastic differentiation [14].
Meanwhile, it is interesting to note that the spindle cell showed positive reactivity for CK CAM 5.2. Although, it has been well known that leiomyosarcoma usually showed negative reactivity for epithelial markers [15], some investigators described that a part of leiomyosarcoma shows positive reactivity for CK [15‐17]. Therefore, CK CAM 5.2 expression in the present case may support a diagnosis of leiomyosarcoma. However, to make diagnosis of leiomyosarcoma with rhabdomyoblastic differentiation, we should refer three important tumors and deny them, respectively, which comprise undifferentiated pleomorphic sarcoma (UPS), rhabdomyosarcoma, and rhabdomyoma. Cardiac UPS usually occurring at the left atrium, histopathologically comprises a mixture of spindle cells in a storiform pattern with polyhedral cells [5]. Furthermore, high-grade undifferentiated sarcomas can exhibit focal α-SMA expression [15]. These findings are similar to the present case. However, the spindle cell, a major component of the present tumor, had an elongated, blunt-ended, and hyperchromatic nucleus plus spindle, fibrillated, and eosinophilic cytoplasm. In addition, the cell showed positive reactivity both for α-SMA and desmin, focally, by immunohistochemical examination. These findings allowed disclosing the smooth muscle differentiation. Furthermore, some of the spindle cell also showed positive reactivity for CK CAM 5.2, of which positive ratio has been reported ranging from 22.2% (2/9) to 35.0% (14/40) in leiomyosarcoma [16, 17]. Although it still remains a difficulty for decision, we made the diagnosis of leiomyosarcoma rather than UPS. On the other hand, since rhabdomyosarcoma has been know as the second most common primary cardiac malignant tumor [2], that should also be considered as a disease for differential diagnosis. Especially, embryonal rhabdomyosarcoma usually shows similar morphologic findings of the present case, such as varying degrees of cellularity containing hypercellular and loosely textured myxoid areas, hyperchromatic and round or spindle-shaped nucleus, and eosinophilic cytoplasm [18]. However, embryonal rhabdomyosarcoma is uncommon in patients older than 40 years of age [18] and neither cross-striation nor myoglobin expression was proven in the present case. Furthermore, a large body of spindle cells showed negative reactivity for myogenin (only 2.1% of them showed positive reactivity) that has been largely accepted as a sensitive and specific immunohistochemical marker for rhabdomyosarcoma or other tumors with rhabdomyoblastic differentiation [14]. According to our immunohistochemical examinations, we were able to deny typical rhabdomyosarcoma. As for rhabdomyoma, the most common subtype of cardiac origin has been known as cardiac rhabdomyoma, but it occurs almost exclusively in the hearts of infants and young children and composes predominantly large polygonal vacuolated spider cells [19]. Therefore, the adult type of rhabdomyoma should be considered as differential diagnosis which is usually composed of tightly polygonal cells which had peripherally placed nucleus plus acidophilic, finely granular, and vacuolated cytoplasm. However, mitotic figures are nearly absent, cross-striations can be discerned, and show positive reactivity for rhabdomyogenic markers immunohistochemically in these two subtypes of rhabdomyoma [19]. These results were different from the findings extracted from the present case.
On the other hand, only one case of sarcoma arisen from myocardium with rhabdomyoblastic differentiation has been reported by Kabir et al. [20] who described a malignant peripheral nerve sheath tumor indicated an area of rhabdomyoblastic differentiation in part. In their report, a little information of immunohistochemical examinations was described which simply comprised positive reactivity for s-100 protein and focal for desmin. These results were different from these of the present case, but comparative discussion could not be completed in detail. Therefore, we preferred to diagnose this primary cardiac malignant tumor as a leiomyosarcoma with partial rhabdomyoblastic differentiation. Previous studies of leiomyosarcoma with rhabdomyoblastic differentiation have conducted to those arisen from another site, and Oshiro et al. have reported that leiomyosarcoma with rhabdomyoblastic differentiation shows poorer prognosis than typical leiomyosarcoma [6]. In fact, the present case showed rapid growth of the tumor and the patient died due to extensive metastases in the lungs despite early diagnosis and surgical removal. Table 2 presented herein summarizes major clinical data of nineteen cases of leiomyosarcoma in soft tissue with rhabdomyoblastic differentiation, and includes the present case representing the first report of leiomyosarcoma arising from the myocardium [table 2]. The patient age ranged from 33 to 85 (mean: 62.7). The male-to-female ratio was 10:10. The tumor sizes ranged from 20 to 250 mm (mean: 116.4).
Table 2
Literature summary of cases of leiomyosarcoma with rhabdomyoblastic differentiation
NR: not reported, DOD: died of disease, NED: no evidence of disease, mo: months
There are twenty cases of leiomyosarcoma with rhabdoid differentiation including the present case.
We wish to take a more detailed discussion on the present case, especially in relation to tumor cell differentiation with phenotypical expression analysis. The spindle cell, a major component of the tumor, has the potential to differentiate into a smooth muscle cell which can be phenotypically identified with positive reactivity for α-SMA. However, we found 2.1% of spindle cells showed positive reactivity for myogenin, and half of myogenin-positive spindle cells showed positive reactivity for α-SMA at the same time. In contrast, none of polyhedral cells showed positive reactivity for α-SMA, but they exhibited a significantly higher myogenin-positive rate than spindle cells. These findings support the following hypothesis. First, the "rhabdomyoblastic differentiation" observed in the present case may represent the early stage of rhabdomyogenic differentiation because tumor cells showed positive reactivity for myogenin which has been known as a maker of cells in the early phase of rhabdomyogenic differentiation, and exhibited neither cross-striation nor myoglobin expression. Second, polyhedral cells may be in a more advanced stage of rhabdomyogenic differentiation than spindle cells because polyhedral cells were morphologically similar to rhabdomyoblasts and showed a significantly higher myogenin-positive rate than spindle cells.
Finally, the possibility of transdifferentiation or synchronous smooth and skeletal muscle differentiation in leiomyosarcoma was suggested in the present case because synchronous expression of α-SMA and myogenin was confirmed in 1.0% of spindle cells. Overall, our immunohistochemical evaluation indicated that rhabdomyoblastic differentiation in leiomyosarcoma might be generated not only by de novo generation from mesenchymal cells.
Conclusion
We describe an extremely rare case of primary cardiac leiomyosarcoma with partial rhabdomyoblastic differentiation. The tumor indicated aggressive growth and the patient died despite early diagnosis and surgical removal. Furthermore, our immunohistochemical evaluation suggested that rhabdomyoblastic differentiation in leiomyosarcoma might be generated not only by de novo generation from mesenchymal cells. To the best of our knowledge, this is the first report of primary cardiac leiomyosarcoma with partial rhabdomyoblastic differentiation.
Consent
We could not get the proof of the patient's written and signed consent for the publication because we could not announce disease of our patient to herself due to her family's request. Furthermore, the patient has already died. However her family agreed our proposal using surgical specimen for our research and written informed consent was obtained from the patient's family (as a proxy) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Acknowledgements
This work was supported by the Health Science Research Grants for Research on Emerging and Re-emerging Infectious Diseases (H16-Shinko-6, H19-Shinko-8, and H22-Shinko-8), Measures for Intractable Diseases (H20 nannchi ippann 35) from the Ministry of Health, Labor and Welfare of Japan, by a Grant of the Strategic Basis on Research Grounds for Non-governmental Schools at Heisei 20th from the Ministry of Education, Culture, Sports, Science and Technology Japan to K. S, and Toho University project grant #21-24 to Y. O. The authors thank Manabu Yamada, Rie Takahashi, Tadashi Ide, Tsutomu Hatori, Takayuki Hirano, and Kayoko Shimodaira for their excellent technical support or pathological advice.
Anzeige
Open Access
This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License (
https://creativecommons.org/licenses/by/2.0
), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
Dr. Shibuya reports receiving research grants from Pfizer Japan Inc., Janssen Pharmaceutical K.K., and Dainippon Sumitomo Pharma Co. All authors declare that they have no competing interests.
Authors' contributions
YO conceptualized the case report, integrated the data, and wrote the manuscript as a major contributor; KS carried out the histopathological evaluation and revised the manuscript; AN contributed to management of the patient and revised clinical description; KT contributed to management of the patient and gave final approval to the manuscript as a corresponding author; NK, TN, AM, and MW carried out the histopathologic evaluation and revised histopathological description; MS, NH, KK, and IT carried out the histopathologic evaluation, JY contributed to management of the patient as a chief doctor of Division of Cardiovascular Medicine. All authors have read and approved the final manuscript.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.